3 QUESTIONS ON... Important Differences Between Two New Prostate Cancer Drugs
نویسندگان
چکیده
منابع مشابه
New drugs in prostate cancer
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other...
متن کاملChemotherapy and New Drugs in Prostate Cancer
Prostate cancer (PrC) is the fourth most common cancer (for both sexes combined) and the second most common cancer in men (accounting for 15% of all new male cancer cases), with a worldwide incidence of approximately 1,111,200, a 5-year prevalence of 3,924,000, and a mortality incidence of 307,000 for the year 2012.1 Since the 1990s, the increasing use of prostate-specific antigen (PSA) testing...
متن کاملComparison between two different methods used for IMRT plans QA of Prostate cancer
Introduction: The aim of this study is evaluation of two Quality Assurance methods in sliding window IMRT technique and Determination of gamma index in both methods Materials and Methods: In this study two tools named" Delta4" phantom and " Epiqa" software has been used to perform QA on the treatment plan before the actual treatment by Varian linear acceler...
متن کاملInverse association between nonsteroidal anti-inflammatory drugs and prostate cancer.
BACKGROUND Prostate cancer is considered a major health problem in western countries. Promising results from observational studies on cancer at other sites fuelled the publication of several studies assessing the association between nonsteroidal anti-inflammatory drug (NSAID) use and prostate cancer. However, these studies show conflicting results. METHODS We conducted a cohort study with a n...
متن کاملNew prostate cancer drugs: extending and improving life.
With the advent of new, life-prolonging therapies in advanced prostate cancer, the eff ects of therapy on the disease's most common complications—skeletal-related events and bone pain—and their eff ect in turn on health-related quality of life should be considered in addition to survival outcomes. AFFIRM 1 was a randomized phase 3 study of enzalutamide (an androgen receptor inhibitor) versus pl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2020
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000722656.82361.fb